Payment overview · 2025
General Payments
$376.90
15 reported records · 5 companies
Healthcare provider profile · identity verified
Blake D Hatfield, M.D.
Allopathic & Osteopathic Physicians|General Practice · DALLAS, TX · NPI 1811382062
Verified facts
What the public records show
CMS Open Payments records show Blake D Hatfield, M.D. received $376.90 in general payments during 2025 across 15 reported records.
Gilead Sciences, Inc. accounted for 61.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 319 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Descovy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Isentress by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $232.53 | 61.7% | 9 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $62.72 | 16.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.86 | 11.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.28 | 5.1% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.51 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.90 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $62.72 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.86 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.86 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.86 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
319 | 34 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
294 | 30 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 561 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 430 | 113 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 319 | 34 |
| Descovy | Emtricitabine/Tenofov Alafenam | 294 | 30 |
| Lisinopril | Lisinopril | 280 | 77 |
| Trazodone Hcl | Trazodone Hcl | 237 | 66 |
| Gabapentin | Gabapentin | 232 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 53 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 215 | 24 |
| Losartan Potassium | Losartan Potassium | 208 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 204 | 58 |
| Alprazolam | Alprazolam | 195 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 52 |
| Metformin Hcl | Metformin Hcl | 178 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 159 | 33 |
| Omeprazole | Omeprazole | 143 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 23 |
| Tivicay | Dolutegravir Sodium | 137 | 13 |
| Prezcobix | Darunavir/Cobicistat | 136 | 13 |
| Valacyclovir | Valacyclovir Hcl | 119 | 33 |
| Bupropion Xl | Bupropion Hcl | 113 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 112 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 33 |
| Montelukast Sodium | Montelukast Sodium | 110 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 34 |
| Mounjaro | Tirzepatide | 107 | 19 |
| Metformin Hcl Er | Metformin Hcl | 104 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 100 | 29 |
| Ezetimibe | Ezetimibe | 97 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 24 |
| Finasteride | Finasteride | 92 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 92 | 22 |
| Tramadol Hcl | Tramadol Hcl | 89 | 13 |
| Sertraline Hcl | Sertraline Hcl | 88 | 23 |
| Acyclovir | Acyclovir | 81 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 21 |
| Carvedilol | Carvedilol | 80 | 28 |
| Allopurinol | Allopurinol | 67 | 18 |
| Ozempic | Semaglutide | 67 | 16 |
| Clonazepam | Clonazepam | 64 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 19 |
| Simvastatin | Simvastatin | 64 | 18 |
| Glipizide | Glipizide | 63 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 23 |
| Darunavir | Darunavir | 61 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Pregabalin | Pregabalin | 60 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 17 |
| Isentress | Raltegravir Potassium | 56 | suppressed |
| Celecoxib | Celecoxib | 54 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 14 |
| Fenofibrate | Fenofibrate | 53 | 13 |
| Glimepiride | Glimepiride | 52 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 14 |
| Methylprednisolone | Methylprednisolone | 51 | 39 |
| Meloxicam | Meloxicam | 49 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 17 |
| Furosemide | Furosemide | 48 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Ritonavir | Ritonavir | 47 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 46 | suppressed |
| Trulicity | Dulaglutide | 46 | 16 |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 44 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 13 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 44 | suppressed |
| Lamivudine | Lamivudine | 41 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Testosterone | Testosterone | 37 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Eliquis | Apixaban | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | suppressed |
| Edurant | Rilpivirine Hcl | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Egrifta Sv | Tesamorelin Acetate | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Abacavir | Abacavir Sulfate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Maraviroc | Maraviroc | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Efavirenz | Efavirenz | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Azithromycin | Azithromycin | 21 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Armour Thyroid | Thyroid,pork | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 14 |
| Estradiol | Estradiol | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Ramipril | Ramipril | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Qbrexza | Glycopyrronium Tosylate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Prezista | Darunavir | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Etravirine | Etravirine | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lamivudine Hbv | Lamivudine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $376.90 · 15 records | Gilead Sciences, Inc. | ABRYSVO, CAPVAXIVE, COMIRNATY, OTEZLA, PIFELTRO, PREVNAR 20, REPATHA, Tlando | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error